An ATM genetic mutation affects a gene that helps cells repair damaged DNA. The biggest known risk is a condition called ataxia-telangiectasia in people who inherit two mutated copies of the gene, one from each parent. People who inherit only one mutated copy — called carriers — are generally healthy but have a moderately higher risk of certain cancers, especially breast cancer.
ATM stands for ataxia-telangiectasia mutated. The gene produces a protein that acts as a first responder when DNA strands break. Without working ATM protein, cells are far more vulnerable to damage. How much risk a mutation carries depends on whether you have one altered copy or two, and that distinction matters enormously.
What Does the ATM Gene Normally Do?
The ATM gene provides instructions for making a protein that senses DNA damage and coordinates repair. When a cell’s DNA develops a double-strand break — one of the most serious types of damage — the ATM protein activates a signaling cascade that pauses cell division and recruits repair machinery.
This protein also plays a role in cell cycle control. If DNA damage is too severe to fix, ATM signaling can push the cell toward self-destruction, a safety mechanism that prevents damaged cells from multiplying. Research consistently shows that this checkpoint function is central to how the body suppresses tumors.
Everyone inherits two copies of the ATM gene, one from each parent. A mutation in one or both copies reduces how much functional ATM protein the body can produce. The effects depend on how much function is lost.
What Are The Risks Of An ATM Genetic Mutation?
The risks split into two very different categories depending on whether a person carries one mutation or two. Inheriting two mutated copies causes ataxia-telangiectasia, a serious neurological and immune disorder. Inheriting one mutated copy does not cause that disease, but it does raise cancer risk to some degree.
Carriers of a single ATM mutation are generally healthy. Their cells produce some working ATM protein, which is enough for normal neurological and immune function. The elevated cancer risk in carriers is real but moderate — it is not a certainty, and most carriers never develop cancer.
People with two mutated copies — estimated at roughly 1 in 40,000 to 1 in 100,000 births in the United States — face a much more serious picture. Ataxia-telangiectasia affects movement, immunity, and DNA repair throughout the body. The risks are neurological, immunological, and oncological all at once.
What Is Ataxia-Telangiectasia and How Serious Is It?
Ataxia-telangiectasia is a progressive disorder that typically appears in early childhood. The hallmark is ataxia — difficulty with balance and coordination — which usually becomes noticeable when a child begins walking. Most children with the condition need a wheelchair by adolescence.
The name describes two visible features. Ataxia refers to the loss of motor control. Telangiectasia refers to tiny dilated blood vessels that become visible in the eyes and on the skin, usually appearing in the first years of life.
The condition also weakens the immune system. Many affected children have low levels of certain antibodies and immune cells, making them more vulnerable to respiratory infections. Some research suggests that immune deficiency is a major contributor to reduced life expectancy in this population.
Cancer risk is substantially elevated in people with ataxia-telangiectasia, particularly leukemia and lymphoma. The combination of immune dysfunction and impaired DNA repair creates conditions where cancer can develop more readily. The evidence for this is strong and consistent across decades of clinical observation.
There is no cure for ataxia-telangiectasia. Care focuses on managing symptoms, supporting immunity, and monitoring for cancer. Some clinicians use physical therapy and speech therapy to maintain function, and immunoglobulin replacement may be used in patients with significant antibody deficiency. No large trials have established a single standardized treatment approach for the neurological aspects, and management varies by center.
What Cancer Risks Do ATM Carriers Face?
Carrying one ATM mutation is associated with a moderately increased risk of breast cancer in women. The evidence for this association is well established and has been replicated across multiple large studies. The risk is higher than in the general population but notably lower than the risk carried by BRCA1 or BRCA2 mutations.
Some research also suggests a possible link between ATM carrier status and other cancers, including pancreatic and prostate cancer. The evidence here is less consistent. Studies vary in how strongly they find these associations, and no consensus currently defines a specific screening protocol for ATM carriers beyond standard age-appropriate cancer screening.
It helps to put the numbers in perspective. A mutation in ATM is not a diagnosis of cancer, and it does not mean cancer is inevitable. It is a risk factor — one variable among many, including age, family history, lifestyle, and other genetic factors.
Some clinicians recommend earlier or more frequent breast imaging for ATM carriers, but formal guidelines are not uniform across organizations. Anyone with a known ATM mutation should discuss screening timing with a genetics professional or their physician rather than relying on general guidance.
How Is an ATM Mutation Inherited?
ATM mutations follow an autosomal recessive pattern. That means a person must inherit two mutated copies — one from each parent — to develop ataxia-telangiectasia. Parents who each carry one mutation are typically unaffected themselves.
When two carriers have a child, each pregnancy carries a 1 in 4 chance the child inherits both mutations and develops the condition. There is also a 1 in 2 chance the child inherits one mutation and becomes a carrier, and a 1 in 4 chance the child inherits neither.
Carrier frequency varies by population. Some estimates suggest that roughly 1 in 100 people of European descent carries an ATM mutation, though exact figures vary by study and population. This is why ataxia-telangiectasia can appear in families with no prior history of the disorder.
Genetic testing can identify ATM mutations in carriers and in affected individuals. Testing is typically considered when there is a family history of ataxia-telangiectasia, early-onset breast cancer in the family, or a known mutation in a relative.
What Should Someone With an ATM Mutation Know About Radiation?
Cells with impaired ATM function are more sensitive to ionizing radiation, because ATM is central to repairing the DNA damage radiation causes. This sensitivity is well documented in laboratory studies and has been observed clinically in people with ataxia-telangiectasia.
For people with ataxia-telangiectasia, standard doses of radiation therapy can cause unusually severe reactions. Clinicians typically adjust treatment carefully and use reduced doses when radiation is necessary. This is a recognized clinical consideration, not a theoretical one.
For ATM carriers with only one mutation, the picture is less clear. Some evidence suggests mild increased radiosensitivity, but the clinical significance for standard medical imaging is uncertain. No established guidelines recommend that carriers avoid routine diagnostic X-rays. The doses used in imaging are generally low. Anyone with concerns about a specific procedure should raise them with the treating physician and, where relevant, a genetics specialist.
How Is ATM-Related Risk Assessed and Managed?
There is no single protocol that applies to everyone with an ATM mutation. Management depends on whether a person has one mutation or two, their age, family history, and other risk factors.
For carriers, the focus is typically on cancer risk awareness and appropriate screening. For people with ataxia-telangiectasia, care involves a multidisciplinary approach — neurologists, immunologists, and oncologists working together.
- Genetic counseling to understand inheritance and family implications
- Regular neurological monitoring for people with ataxia-telangiectasia
- Immune function assessment and infection management
- Cancer screening tailored to individual risk
- Careful planning around radiation exposure
No medication currently corrects the underlying ATM defect. Research into treatments is ongoing, but no therapy has been shown in large human trials to restore ATM function or halt the neurological progression of ataxia-telangiectasia. That is the honest state of the science.
Frequently Asked Questions
What is the life expectancy of someone with ataxia-telangiectasia?
Life expectancy is significantly shortened, and many people with the condition survive into their twenties or thirties, though outcomes vary. Cancer and respiratory infections are the most common causes of early death.
Can you have an ATM mutation and never get cancer?
Yes. Most ATM carriers never develop cancer, though their risk is moderately higher than average. A mutation is a risk factor, not a prediction.
Is ATM mutation the same as BRCA?
No. ATM and BRCA are different genes, though both are involved in DNA repair and both affect cancer risk. The cancer risk associated with ATM mutations is generally lower than with BRCA1 or BRCA2 mutations.
Should ATM carriers avoid CT scans and X-rays?
No established guidelines recommend avoiding routine diagnostic imaging for carriers. Some evidence suggests mild radiosensitivity, so it is reasonable to tell any treating physician about the mutation before procedures involving radiation.
